



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



ACSL3 (human, recombinant; aa 45-720)


Item No. 39990

Overview and Properties

Synonyms:	ACSL3, Fatty Acid CoA Ligase 3, LACS 3, Long-chain Acyl-CoA Synthetase 3, Long-chain Fatty Acid-CoA Ligase 3
Source:	Active recombinant human N-Terminal His-tagged ACSL3 expressed in <i>E. coli</i>
Amino Acids:	45-720
Uniprot No.:	P33121
Molecular Weight:	77.19 kDa
Storage:	-80°C (as supplied)
Stability:	≥1 year
Purity:	≥90% estimated by SDS-PAGE
Supplied in:	50 mM Tris pH 8.0, with 150 mM sodium chloride and 10% glycerol
Protein Concentration:	<i>batch specific</i> mg/ml
Activity:	<i>batch specific</i> U/ml
Specific Activity:	<i>batch specific</i> U/mg
Unit Definition:	One unit is defined as the amount of enzyme required to measure the change of free fatty acid concentration in μM per minute at 37 °C.


Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Images



Lane 1: MW Markers
Lane 2: ACSL3 (2 μg)
Lane 3: ACSL3 (4 μg)

SDS-Page Analysis of ACSL3. This protein has a calculated molecular weight of 77.19 kDa.



ACSL3 enzyme activity was determined using Cayman's Free Fatty Acid Fluorometric Assay Kit (Item No. 700310) with 100 μM oleic acid as the substrate.

WARNING
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/20/2024

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM

PRODUCT INFORMATION



Description

Long-chain acyl-CoA synthetase 3 (ACSL3) is an enzyme involved in lipid biosynthesis and fatty acid degradation.¹ It is composed of short N- and C-terminal domains surrounding an AMP-binding domain.² It is expressed in the brain and prostate and localizes to the endoplasmic reticulum, mitochondria, and lipid droplets.¹ ACSL3 is activated by a variety of factors, including peroxisome proliferator-activated receptor δ (PPAR δ), octamer-binding transcription factor 1 (Oct1), and the liver X receptor (LXR), among others. ACSL3 converts free monounsaturated long-chain fatty acids into fatty acyl-CoA esters, which are used as substrates for phospholipid and glycerolipid biosynthesis or transported into the mitochondria to be degraded via fatty acid β -oxidation for use as an energy source.^{1,3,4} ACSL3-dependent conversion of exogenous MUFAs into fatty acyl-CoA esters can induce resistance to ferroptotic cell death by displacing PUFAs and preventing the accumulation of lipid reactive oxygen species (ROS) in the plasma membrane.^{3,5} ACSL3 is required for tumor cell survival in non-small cell lung cancer (NSCLC) mouse xenograft models, including those expressing K-Ras containing the glycine-to-aspartate activating mutation at position 12 (K-Ras^{G12D}).⁶ It is also highly expressed in tumor tissues isolated from patients with early-stage NSCLC. In contrast, homozygous deletion of ACSL3 is associated with an increased risk of metastasis or recurrence in patients with triple-negative breast cancer (TNBC) receiving adjuvant chemotherapy.⁷ Cayman's ACSL3 (human, recombinant) protein can be used for ELISA, enzyme activity assay, and Western blot applications.

References

1. Quan, J., Bode, A.M., and Luo, X. ACSL family: The regulatory mechanisms and therapeutic implications in cancer. *Eur. J. Pharmacol.* **909**:174397, (2021).
2. Poppelreuther, M., Rudolph, B., Du, C., *et al.* The N-terminal region of acyl-CoA synthetase 3 is essential for both the localization on lipid droplets and the function in fatty acid uptake. *J. Lipid Res.* **53**(5), 888-900 (2012).
3. Dixon, S.J. and Olzmann, J.A. The cell biology of ferroptosis. *Nat. Rev. Mol. Cell Biol.* (2024).
4. Yang, Y., Zhu, T., Wang, X., *et al.* ACSL3 and ACSL4, distinct roles in ferroptosis and cancers. *Cancers (Basel)* **14**(23), 5896 (2022).
5. Magtanong, L., Ko, P.-J., To, M., *et al.* Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. *Cell Chem. Biol.* **26**(3), 420-432 (2019).
6. Padanad, M.S., Konstantinidou, G., Venkateswaran, N., *et al.* Fatty acid oxidation mediated by acyl-CoA synthetase long chain 3 is required for mutant KRAS lung tumorigenesis. *Cell Rep.* **16**(6), 1614-1628 (2016).
7. Jeong, H.M., Kim, R.N., Kwon, M.J., *et al.* Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patients. *Oncotarget* **8**(37), 61538-61550 (2017).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM